C
Creabilis
Specialty pharmaceutical company focused on dermatology
About Creabilis
Creabilis SA is a dynamic startup that operates in the online gambling industry. The company specializes in providing a comprehensive platform for online betting, including poker, slot games, and various other forms of online gambling. Creabilis SA caters primarily to adult users who are interested in online gaming and betting, offering them a secure and engaging environment to place their bets and play their favorite games.
The market Creabilis SA operates in is the global online gambling market, which has seen significant growth over the past few years. This market is driven by the increasing penetration of the internet and smartphones, which makes online gambling more accessible to a broader audience. The company’s target clients are typically individuals who enjoy the thrill of gambling and are looking for a reliable and user-friendly platform to do so.
Creabilis SA’s business model is based on providing a seamless online gambling experience through its website. The company makes money primarily through the bets placed by users on its platform. Additionally, it may generate revenue through advertising and partnerships with other companies in the gambling industry. The platform likely charges a commission or fee on each bet placed, which is a common practice in the online gambling sector.
In summary, Creabilis SA is focused on delivering a top-notch online gambling experience to its users. By leveraging the growing trend of online gaming, the company aims to establish itself as a leading player in the market. Its revenue model is straightforward, relying on user bets and potential advertising partnerships to drive growth.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2003
- Headquarters
- Canterbury, United Kingdom
- Open positions
- None listed
- Dealroom signal
- 25.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Developer Tools, Biotechnology, Dermatology, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, uk is8 life sciences, science-based
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Dec 2016 | $0 | — | Sienna Biopharmaceuticals | — |
| SERIES B✓Equity / VC | Oct 2011 | $20M | $80M | Sofinnova Partners · Abbott Biotech Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Creabilis is 170 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
NeoMed
Sofinnova Partners- AVAbbott Biotech Ventures
Other known investors1 additional known investor
Sienna Biopharmaceuticals
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Creabilis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Creabilis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.